title: A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
abstract: A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.
authors.affiliation: Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
authors.forename: Randolph S
authors.initials: RS
authors.lastname: Marks
authors.forename: David L
authors.initials: DL
authors.lastname: Graham
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.forename: Shauna
authors.initials: S
authors.lastname: Hillman
authors.forename: Steven
authors.initials: S
authors.lastname: Fishkoff
authors.forename: James E
authors.initials: JE
authors.lastname: Krook
authors.forename: Scott H
authors.initials: SH
authors.lastname: Okuno
authors.forename: James A
authors.initials: JA
authors.lastname: Mailliard
authors.forename: Tom R
authors.initials: TR
authors.lastname: Fitch
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Addo
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D047630:Depsipeptides; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D009842:Oligopeptides; C075610:dolastatin 15; C094621:cemadotin